The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Pharmacodynamics of Caspofungin in a Murine Model of Invasive Pulmonary Aspergillosis: Evidence of Concentration‐Dependent Activity
Abstract
BACKGROUND: A paucity of data exists regarding the pharmacodynamics of caspofungin (CAS) during invasive pulmonary aspergillosis (IPA). We conducted a dosage-fractionation study to characterize the in vivo pharmacodynamics of CAS activity during IPA, using immunosuppressed mice inoculated intranasally with Aspergillus fumigatus. METHODS: After single intraperitoneal doses (0.25, 1.0, and 4.0 mg/kg), plasma CAS concentrations were assayed by high-performance liquid chromatography. The pharmacokinetic data were analyzed by nonparametric population pharmacokinetic analysis. Three dosage groups (0.25, 1.0, and 4.0 mg/kg) fractionated into 3 different dosing intervals (q6, q24, or q48 h) were then used to evaluate the pharmacokinetic/pharmacodynamic effects (percentage of time greater than the minimum effective concentration [MEC], 96-h area under the plasma concentration curve:MEC ratio, and peak concentration in plasma [Cmax]:MEC ratio) at clinically achievable exposures. Mice were treated for 96 h and were then euthanized, and their lungs were harvested for analysis of pulmonary fungal burden by real-time quantitative polymerase chain reaction. RESULTS: A concentration-dependent reduction in mean pulmonary fungal burden was evident in mice in the 1 mg/kg dosage-fractionation group, with significantly lower mean pulmonary fungal burden in mice dosed q48 h versus q6 h (P < .01). A paradoxical increase in pulmonary fungal burden was observed in the highest dosage-fractionation group. CONCLUSIONS: CAS demonstrates concentration-dependent pharmacodynamics in the treatment of IPA. The Cmax : MEC ratio appears to be the parameter most closely associated with the reduction of pulmonary fungal burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303
Compounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242
Safety and tolerability of caspofungin acetate in the treatment of fungal infections
Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.01004.x · Cited by 148
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Current Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 377
Self-citationEchinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Current Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
New and emerging treatments for fungal infections
Pasqualotto, A. C., & Denning, D. W. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm428 · Cited by 173
Cramer, R. A., Perfect, B. Z., Pinchai, N., Park, S., Perlin, D. S., Asfaw, Y. G., Heitman, J., Perfect, J. R., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00086-08 · Cited by 172
Chamilos, G., Lewis, R. E., Albert, N., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00095-07 · Cited by 171
Self-citationFortwendel, J. R., Juvvadi, P. R., Perfect, B. Z., Rogg, L. E., Perfect, J. R., & Steinbach, W. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00854-09 · Cited by 153
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140
Self-citationEchinocandins for the treatment of invasive aspergillosis: from laboratory to bedside
Aruanno, M., Glampedakis, E., & Lamoth, F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00399-19 · Cited by 136
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
Wiederhold, N. P., Kontoyiannis, D. P., Prince, R. A., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5146-5148.2005 · Cited by 131
Self-citationStimulated Innate Resistance of Lung Epithelium Protects Mice Broadly against Bacteria and Fungi
Evans, S. E., Scott, B. L., Clement, C. G., Larson, D. T., Kontoyiannis, D., Lewis, R. E., LaSala, P. R., Pawlik, J., Peterson, J. W., Chopra, A. K., et al. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0260oc · Cited by 129
Self-citationJuvvadi, P. R., Lamoth, F., & Steinbach, W. J. (2014) · Fungal Biology Reviews · doi:10.1016/j.fbr.2014.02.004 · Cited by 116
Muszkieta, L., Aimanianda, V., Mellado, E., Gribaldo, S., Alcàzar-Fuoli, L., Szewczyk, E., Prevost, M.-C., & Latgé, J.-P. (2014) · Cellular Microbiology · doi:10.1111/cmi.12326 · Cited by 110
Echinocandins: the expanding antifungal armamentarium
Aguilar-Zapata, D., Petraitiene, R., & Petraitis, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ814 · Cited by 112
The eagle effect and antibiotic-induced persistence: two sides of the same coin?
Prasetyoputri, A., Jarrad, A. M., Cooper, M. A., & Blaskovich, M. A. T. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.10.007 · Cited by 101
Wiederhold, N. P., Locke, J. B., Daruwala, P., & Bartizal, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky280 · Cited by 91
Self-citationRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
Lamoth, F., Juvvadi, P. R., Gehrke, C., Asfaw, Y. G., & Steinbach, W. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit530 · Cited by 62
Desoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
Lewis, R. E., Chamilos, G., Prince, R. A., & Kontoyiannis, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01268-06 · Cited by 51
Self-citationSiopi, M., Siafakas, N., Vourli, S., Mouton, J. W., Zerva, L., & Meletiadis, J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw276 · Cited by 23
Lewis, R. E., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr142 · Cited by 23
Self-citationRammaert, B., Jouvion, G., de Chaumont, F., Garcia-Hermoso, D., Szczepaniak, C., Renaudat, C., Olivo-Marin, J.-C., Chrétien, F., Dromer, F., & Bretagne, S. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.04.027 · Cited by 22
Bayegan, S., Majoros, L., Kardos, G., Kemény-Beke, A., Miszti, C., Kovacs, R., & Gesztelyi, R. (2010) · The Journal of Microbiology · doi:10.1007/s12275-010-9221-y · Cited by 21
Metadata
- Authors
- Wiederhold, N. P., Kontoyiannis, D. P., Chi, J., Prince, R. A., Tam, V. H., & Lewis, R. E.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10-15
- Volume
- 190
- Issue
- 8
- Pages
- 1464-1471
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2143363666
- Cited by
- 207
- References
- 4
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.